AGIO | Agios Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	57.45 - 58.77
52 Week Range	20.96 - 62.58
Beta	0.80
Implied Volatility	56.90%
IV Rank	40.96%
Day's Volume	86,232
Average Volume	574,715
Shares Outstanding	57,030,200
Market Cap	3,298,626,768
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-07-24

Valuation
Profitability
Growth
Health
P/E Ratio	4.96
Forward P/E Ratio	N/A
EPS	11.66
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	383
Country	USA
Website	AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO's peers: ACET, ADAP, MREO, BPMC, DAWN, BMRN, IDYA, ANAB, MGTX, KROS, FIXX, KYMR, RVMD, CCCC, NRIX, RLAY, STOK, PLRX, BDTX, ARVN, SNDX, COGT, CGEM, KALV, MRSN, ALVR, BHVN, BLUE, CORT, FGEN, FOLD, HALO, INSM, KPTI, MRVI

*Chart delayed

Analyzing fundamentals for AGIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong. For more detailed analysis please see AGIO Fundamentals page.

Watching at AGIO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AGIO Technicals page.